JPS5611436B2 - - Google Patents

Info

Publication number
JPS5611436B2
JPS5611436B2 JP11842677A JP11842677A JPS5611436B2 JP S5611436 B2 JPS5611436 B2 JP S5611436B2 JP 11842677 A JP11842677 A JP 11842677A JP 11842677 A JP11842677 A JP 11842677A JP S5611436 B2 JPS5611436 B2 JP S5611436B2
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP11842677A
Other languages
Japanese (ja)
Other versions
JPS5452794A (en
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to JP11842677A priority Critical patent/JPS5452794A/ja
Priority to US05/947,103 priority patent/US4197290A/en
Priority to GB7838618A priority patent/GB2009771B/en
Priority to FR7828133A priority patent/FR2410043A1/fr
Publication of JPS5452794A publication Critical patent/JPS5452794A/ja
Priority to FR8022285A priority patent/FR2468372A1/fr
Publication of JPS5611436B2 publication Critical patent/JPS5611436B2/ja
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/823—Bacterial vaccine for bovine species, e.g. cattle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP11842677A 1977-09-30 1977-09-30 Extracting of polysacchride from capusle containing epidermis staphylococus Granted JPS5452794A (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP11842677A JPS5452794A (en) 1977-09-30 1977-09-30 Extracting of polysacchride from capusle containing epidermis staphylococus
US05/947,103 US4197290A (en) 1977-09-30 1978-09-29 Vaccine
GB7838618A GB2009771B (en) 1977-09-30 1978-09-29 Vaccine
FR7828133A FR2410043A1 (fr) 1977-09-30 1978-10-02 Nouveau vaccin contre la mammite de la vache et son procede de production
FR8022285A FR2468372A1 (fr) 1977-09-30 1980-10-17 Nouveau vaccin contre les maladies infectieuses chez les bovins et son procede de production

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP11842677A JPS5452794A (en) 1977-09-30 1977-09-30 Extracting of polysacchride from capusle containing epidermis staphylococus

Publications (2)

Publication Number Publication Date
JPS5452794A JPS5452794A (en) 1979-04-25
JPS5611436B2 true JPS5611436B2 (enExample) 1981-03-14

Family

ID=14736342

Family Applications (1)

Application Number Title Priority Date Filing Date
JP11842677A Granted JPS5452794A (en) 1977-09-30 1977-09-30 Extracting of polysacchride from capusle containing epidermis staphylococus

Country Status (4)

Country Link
US (1) US4197290A (enExample)
JP (1) JPS5452794A (enExample)
FR (2) FR2410043A1 (enExample)
GB (1) GB2009771B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62165286U (enExample) * 1986-04-07 1987-10-20

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327082A (en) * 1979-07-12 1982-04-27 Adcock-Ingram Laboratories Limited Mastitis vaccination
US4425330A (en) 1981-05-20 1984-01-10 Cornell Research Foundation, Inc. Bovine mastitis vaccine and method for detecting efficacy thereof
US4762712A (en) * 1983-08-31 1988-08-09 Stolle Research & Development Corporation Anti-mastitis polyvalent vaccine, method of administration and method for production thereof
DE3345864A1 (de) * 1983-12-19 1985-06-27 Egbert Frh. von 8000 München Malsen-Ponickau Impfstoff und verfahren zu seiner herstellung
FR2619122B1 (fr) * 1987-08-03 1990-03-09 Pasteur Institut Procede d'obtention de polyosides capsulaires de staphylocoques, polyosides obtenus, applications de ces polyosides et souches pour la mise en oeuvre du procede
US5034515A (en) * 1987-09-22 1991-07-23 Wisconsin Alumni Research Foundation Staphylococcal fibronectin receptor, monoclonal antibodies thereto and methods of use
US5055455A (en) * 1988-09-28 1991-10-08 Brigham And Women's Hospital Capsular polysaccharide adhesin antigen, preparation, purification and use
US7279162B1 (en) * 1990-10-22 2007-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Isolated broadly reactive opsonic immunoglobulin for treating a pathogenic coagulase-negative staphylococcus infection
US5955074A (en) * 1990-10-22 1999-09-21 Henry M. Jackson Foundation For The Advancement Of Military Medicine Directed human immune globulin for the prevention and treatment of staphylococcal infections
US5571511A (en) * 1990-10-22 1996-11-05 The U.S. Government Broadly reactive opsonic antibodies that react with common staphylococcal antigens
US20080139789A1 (en) * 1990-10-22 2008-06-12 Henry M. Jackson Foundation For The Advancement Of Military Medicine Isolated Broadly Reactive Opsonic Immunoglobulin for Treating a Pathogenic Coagulase-Negative Staphylococcus Infection
AU681573B2 (en) * 1991-11-22 1997-09-04 Glaxosmithkline Biologicals Sa Type I and type II surface antigens associated with (staphylococcus epidermidis)
US5980908A (en) * 1991-12-05 1999-11-09 Alfa Laval Ab Bacterial cell surface protein with fibronectin, fibrinogen, collagen and laminin binding ability, process for the manufacture of the protein and prophylactic treatment
AU673508B2 (en) * 1992-02-25 1996-11-14 Henry M. Jackson Foundation For The Advancement Of Military Medicine Directed human immune globulin for the prevention and treatment of staphylococcal infections
US6610293B1 (en) * 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
US7250494B2 (en) * 1998-06-15 2007-07-31 Biosynexus Incorporated Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
US7252828B2 (en) 1998-07-15 2007-08-07 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
US6984381B2 (en) 2002-07-05 2006-01-10 The United States Of America As Represented By The Secretary Of Agriculture Vaccine for the prevention of bacterial infection of the bovine mammary gland
AU2003295520B8 (en) 2002-11-12 2011-05-19 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for Staphylococcal infections
AU2003290867A1 (en) * 2002-11-12 2004-06-03 The Brigham And Women's Hospital, Inc. Methods and products for treating staphylococcal infections
EP1745075B1 (en) * 2004-04-21 2013-04-03 The Brigham And Women's Hospital, Inc. Poly-n-acetyl glucosamine (pnag/dpnag)-binding peptides and methods of use thereof
MX2007003402A (es) 2004-09-22 2007-05-10 Glaxosmithkline Biolog Sa Composicion inmunogena para su uso en vacunacion contra estafilococos.
PH12013500136A1 (en) 2006-03-30 2015-03-13 Glaxosmithkline Biologicals Sa Immunogenic composition
CN105085349B (zh) 2008-07-21 2018-02-09 布赖汉姆妇女医院 与合成的β‑1,6 葡糖胺寡糖相关的方法和组合物
CN102333540B (zh) 2008-10-06 2015-04-22 芝加哥大学 与细菌eap、emp和/或adsa蛋白相关的组合物和方法
RU2403283C2 (ru) * 2008-12-30 2010-11-10 Общество с ограниченной ответственностью "БиоМедВет" Штамм staphylococcus epidermidis bvm-1987 - продуцент стафилолитического ферментного комплекса
TW201043267A (en) * 2009-03-19 2010-12-16 Intervet Int Bv In situ constituting a vaccine for administration to a predetermined herd of animals
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
US8974799B2 (en) 2009-09-30 2015-03-10 Novartis Ag Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides
SI2493498T1 (sl) 2009-10-30 2017-07-31 Glaxosmithkline Biologicals Sa Čiščenje kapsularnih saharidov Staphylococcusa aureusa tipa 5 in tipa 8
US20130315959A1 (en) 2010-12-24 2013-11-28 Novartis Ag Compounds
WO2013038375A2 (en) 2011-09-14 2013-03-21 Novartis Ag Methods for making saccharide-protein glycoconjugates
AU2012335208B2 (en) 2011-11-07 2017-08-31 Glaxosmithkline Biologicals S.A. Carrier molecule comprising a spr0096 and a spr2021 antigen
GB201121301D0 (en) 2011-12-12 2012-01-25 Novartis Ag Method
SG10201608675YA (en) 2012-05-22 2016-12-29 Novartis Ag Meningococcus serogroup x conjugate
CN117866859A (zh) * 2018-01-05 2024-04-12 阿兹特拉公司 葡萄球菌属细菌的营养缺陷型菌株
WO2020163512A1 (en) 2019-02-05 2020-08-13 The Brigham And Women's Hospital, Inc. Polysaccharide compositions for use in treating filariasis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL262599A (enExample) * 1900-01-01
NL278429A (enExample) * 1900-01-01
DE1154234B (de) * 1960-03-21 1963-09-12 Parke Davis & Co Verfahren zur Herstellung einer Staphylococcenvaccine
GB925124A (en) * 1960-03-21 1963-05-01 Parke Davis & Co Staphylococcal vaccine
FR1334930A (fr) * 1961-03-20 1963-08-16 Parke Davis & Co Procédé de production d'un antigène nouveau par extraction de culture de staphylocoques
DE1185335B (de) * 1961-05-15 1965-01-14 Parke Davis & Co Verfahren zur Herstellung von neuen Staphylococcen-Antigenen
US3269913A (en) * 1962-05-11 1966-08-30 Parke Davis & Co Staphylococcal-immunizing products and methods for their production
GB995338A (en) * 1963-09-20 1965-06-16 Parke Davis & Co Polysaccharides and methods for their production
JPS5520268B2 (enExample) * 1972-07-15 1980-05-31

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62165286U (enExample) * 1986-04-07 1987-10-20

Also Published As

Publication number Publication date
FR2410043A1 (fr) 1979-06-22
US4197290A (en) 1980-04-08
FR2468372A1 (fr) 1981-05-08
GB2009771B (en) 1982-07-14
JPS5452794A (en) 1979-04-25
FR2410043B1 (enExample) 1983-09-09
FR2468372B1 (enExample) 1983-10-14
GB2009771A (en) 1979-06-20

Similar Documents

Publication Publication Date Title
FR2468372B1 (enExample)
DE2857901A1 (enExample)
FR2377915B1 (enExample)
FR2378094B2 (enExample)
FR2378161B1 (enExample)
FR2376912B3 (enExample)
FR2378212B1 (enExample)
FR2378206B2 (enExample)
FR2378124B1 (enExample)
DE7734063U1 (enExample)
FR2367205B2 (enExample)
FR2376932B3 (enExample)
DK180777A (enExample)
DK585278A (enExample)
FR2377821B1 (enExample)
DK367677A (enExample)
BG25841A1 (enExample)
BG25852A1 (enExample)
BG25848A1 (enExample)
BG25847A1 (enExample)
BG25845A1 (enExample)
BG25844A1 (enExample)
BG25851A1 (enExample)
BG25840A1 (enExample)
BG25839A1 (enExample)